Why the study?
The HEART and EDACS scores are widely used to risk-stratify ED patients with chest pain, but direct comparison with the newer SVEAT score is limited.
Population
1263 consecutive adults with non-traumatic chest pain at a Turkish tertiary care ED
Comparison
HEART vs SVEAT vs EDACS scores alone and combined with a serial hs-cTnT rule
Design
Single-centre retrospective secondary analysis of a prospectively collected registry
Follow-up
30 days
Answers are grounded in this paper and cite their sources.
Retrospective registry analysis evaluates chest pain risk scores for predicting 30-day death or intervention, indicating standalone tools miss unacceptable rates of adverse events.
Background/Objectives: The HEART and EDACS scores are widely used to risk-stratify emergency department (ED) patients with chest pain, but direct comparison with the newer SVEAT score is limited. We compared all three scores in one cohort with a high event rate, each alone and combined with the same serial high-sensitivity troponin T (hs-cTnT) rule. Methods: In a retrospective secondary analysis of a prospectively collected registry at a Turkish tertiary care ED (April–August 2022), 1263 consecutive adults with non-traumatic chest pain were included. Three investigators who did not collect the outcome data calculated the HEART, EDACS and SVEAT scores from the clinical records. The outcome was 30-day all-cause death or percutaneous coronary intervention (PCI); myocardial infarction was not recorded as a separate outcome. Low risk was defined as HEART ≤ 3, SVEAT ≤ 4 and EDACS < 16; pathways added hs-cTnT < 14 ng/L at 0 h and 2 h. Results: The outcome occurred in 151 of 1263 patients (12.0%). HEART and SVEAT had similar discrimination (area under the curve [AUC] 0.845 versus 0.842; DeLong p = 0.824), and both exceeded standalone EDACS (0.735; both p < 0.001). Among patients classified as low risk by the score alone, the outcome occurred in 4.5% (HEART), 5.9% (SVEAT) and 7.4% (EDACS). With serial troponin, miss rates were 1.7%, 2.0% and 1.8%, respectively, and no significant difference in sensitivity was detected. Conclusions: In this high-prevalence cohort none of the scores alone reached an acceptable miss rate, and no pathway reached a 1% miss rate at the point estimate. The findings are from a single centre, are not externally validated and are subject to overlap between troponin and the outcome.
No takes yet. Share an insight, caveat, or question.
Ünal et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: